Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

Retrieved on: 2021-04-12 11:02:59

Tags for this article:

Click the tags to see associated articles and topics

Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study. View article details on hiswai:

Excerpt

Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients. - Pelareorep alone and with ...

Article found on: www.prnewswire.com